Core Insights - Aspire Biopharma has filed a provisional patent application for a fast-acting sublingual powder formulation of ondansetron, the active ingredient in Zofran, aimed at providing rapid relief from nausea caused by cancer treatments [1] - The global ondansetron market was valued at approximately $1.4 billion in 2023 and is projected to grow to $2.4 billion by 2032, driven by increasing cancer incidences and surgical procedures [1] Company Developments - Aspire's new sublingual delivery system is designed to bypass the gastrointestinal tract, potentially reducing the onset of action from 30 minutes to just minutes, thus providing near-instant absorption [1] - The company plans to utilize the FDA's 505(b)(2) regulatory pathway to streamline clinical development and reduce time-to-market for its new formulation [1] Market Positioning - Ondansetron was the 53rd most prescribed medication in the U.S. in 2023, with over 12.5 million prescriptions, indicating significant market utilization [1] - The sublingual formulation specifically addresses the unmet need for patients who cannot swallow tablets due to severe vomiting or gastric irritation [1]